Dentsply SironaXRAY +3.14%55 EBITDA Margin % is 6.93% as of Mar. 2026, which is 175% above its 10-year median of 2.52. GuruFocus rates XRAY with a GF Score™ of 55/100 and a GF Value™ of $19.06 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Dentsply Sirona ranks worse than 63.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dentsply Sirona's EBITDA for the
three
months ended in Mar. 2026 was $61 Mil. Dentsply Sirona's Revenue for the
three
months ended in Mar. 2026 was $880 Mil. Therefore, Dentsply Sirona's EBITDA margin for the quarter that ended in Mar. 2026 was 6.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dentsply Sirona EBITDA Margin % Related Terms
Dentsply Sirona EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dentsply Sirona's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XRAY vs LMAT, PLSE, NNNN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Dentsply Sirona's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dentsply Sirona EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dentsply Sirona's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dentsply Sirona's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dentsply Sirona (XRAY) has a EBITDA Margin % of 6.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dentsply Sirona and its competitors. This is 175% above median its historical median of 2.52. According to the industry distribution chart, Dentsply Sirona ranks #522 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 64%.
Is Dentsply Sirona's EBITDA Margin % too high?
Dentsply Sirona's current EBITDA Margin % of 6.93% is 175% above median its 10-year median of 2.52. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Dentsply Sirona's value of 6.93% is 7.3% below this industry median. Based on the distribution chart, Dentsply Sirona ranks #522 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Dentsply Sirona has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dentsply Sirona's EBITDA Margin % compare to LMAT and PLSE?
According to the Medical Devices & Instruments industry distribution chart, Dentsply Sirona ranks #522 out of 816 companies for EBITDA Margin %. This places Dentsply Sirona in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Dentsply Sirona's value of 6.93% is 7.3% below this benchmark. While the company's 10-year median is 2.52 vs. the industry median of 7.48, Dentsply Sirona has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dentsply Sirona's current EBITDA Margin % of 6.93% is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dentsply Sirona and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dentsply Sirona's current EBITDA Margin % is 6.93%, which is 175% above median its own 10-year median of 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dentsply Sirona stock overvalued right now?
Based on GuruFocus' analysis, Dentsply Sirona (XRAY) is currently considered Possible Value Trap. The stock's GF Value™ is $19.06, compared to a current price of $10.52 — trading 44.8% below its estimated fair value. The current EBITDA Margin % is 6.93%, which is 175% above median its 10-year median of 2.52 and 7.3% below the Medical Devices & Instruments industry median of 7.48. Dentsply Sirona's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dentsply Sirona (XRAY), the current EBITDA Margin % is 6.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dentsply Sirona (XRAY) Overvalued in 2026?
Based on GuruFocus' analysis, Dentsply Sirona stock appears to be undervalued.
The current stock price of $10.52 is trading 44.8% below its estimated GF Value™ of $19.06.
GuruFocus considers Dentsply Sirona to be Possible Value Trap.
Key valuation signals for XRAY:
EBITDA Margin %: 6.93% (175% above median its 10-year median of 2.52)
GF Value™: $19.06 vs. price of $10.52 (44.8% below fair value)
Industry Position: 7.3% below the Medical Devices & Instruments median (#522 of 816)
No single metric tells the full story. See the XRAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
55GF Score
Get the complete analysis for XRAY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XRAY has been successfully added to your 
